Johnson and Johnson 2012 Annual Report Download - page 6

Download and view the complete annual report

Please find page 6 of the 2012 Johnson and Johnson annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 83

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75
  • 76
  • 77
  • 78
  • 79
  • 80
  • 81
  • 82
  • 83

2012 Business Segment Highlights
Johnson & Johnson delivered solid results in 2012, reflecting continued sales momentum in many parts of our business
driven by our focus on delivering meaningful innovation in health care to patients and customers. Our results included
strong growth of key products, successful new product launches, and the addition of Synthes to our family of companies.
In addition, we continued to make important investments building strategic partnerships and in advancing our pipeline,
positioning us well for delivering sustainable growth.
Pharmaceutical Segment Sales
Sales by Therapeutic Area (in billions of dollars)
2012 Sales: $25.4 billion
Sales Change:
Total: 4.0%
Operational*: 6.8%
* Operational excludes the impact of currency.
** Rounded for visual accuracy.
INFECTIOUS DISEASES
$3.2
0.2%
ONCOLOGY
$2.6
28.4%
OTHER
$5.0**
(8.3%)
NEUROSCIENCE
$6.7
(3.3%)
IMMUNOLOGY
$7.9
15.8%
Medical Devices and Diagnostics
Segment Sales
Sales by Major Franchise (in billions of dollars)
2012 Sales: $27.4 billion
Sales Change:
1
Total: 6.4%
Operational*: 8.7%
ORTHOPAEDICS1
$7.8
34.3%
SURGICAL CARE
$6.5
(2.3%)
SPECIALTY SURGERY
$2.5
4.9%
VISION CARE
$3.0
2.7%
DIABETES CARE
$2.6
(1.4%)
CARDIOVASCULAR
CARE
$2.0
(13.2%)
DIAGNOSTICS
$2.1
(4.4%)
INFECTION
PREVENTION/OTHER
$0.9**
5.1%
(1) Excluding the net impact of the Synthes acquisition, MD&D
total change = (1.5%) and Orthopaedics total change = (0.4%)
Consumer Segment Sales
Sales by Major Franchise (in billions of dollars)
2012 Sales: $14.4 billion
Sales Change:
Total: (2.9%)
Operational*: 0.5%
OTC AND
NUTRITIONALS
$4.4
(1.1%)
SKIN CARE
$3.6
(2.6%)
WOMEN’S HEALTH
$1.6
(9.3%)
WOUND CARE/
OTHER
$1.0
(3.8%)
BABY CARE
$2.2**
(3.7%)
ORAL CARE
$1.6
0.0%
PHARMACEUTICALS
With $25.4 billion in worldwide sales in 2012, we are the eighth-largest pharmaceuticals business in the world and the
sixth-largest biotech business. Primary contributors to strong operational growth of 6.8 percent include REMICADE®
(infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases;
VELCADE®(bortezomib), a treatment for multiple myeloma; PREZISTA®(darunavir), a treatment for HIV; and a
number of recently launched products.
We are accelerating growth while ensuring greater access and reimbursement by implementing strong launch
programs for recently approved products including ZYTIGA®(abiraterone acetate), an oral, once-daily medication for
use in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer; INVEGA®
SUSTENNA®/XEPLION®(paliperidone palmitate), a once-monthly, long-acting, injectable atypical antipsychotic for
treatment of schizophrenia in adults; INCIVO®(telaprevir), a direct-acting antiviral protease inhibitor for the treatment
of genotype-1 chronic hepatitis C virus, in combination with peginterferon alfa and ribavirin, in adults; STELARA®
(ustekinumab), a biologic approved for the treatment of adults with moderate to severe plaque psoriasis; XARELTO®
(rivaroxaban), an oral anticoagulant; and SIMPONI®(golimumab), a biologic approved to treat adults with moderately
to severely active rheumatoid arthritis (RA), active psoriatic arthritis and active ankylosing spondylitis.
2012 BUSINESS SEGMENT HIGHLIGHTS